Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Public ClinicalTrials.gov record NCT00510484. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Multi-center, Placebo-controlled, Cross-over Study to Assess the Efficacy and Safety of Pancrelipase Delayed Release 24,000 Unit Capsules in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Study identification
- NCT ID
- NCT00510484
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- Pancrelipase Delayed Release Drug
- Placebo Comparator Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2007
- Primary completion
- Feb 29, 2008
- Completion
- Feb 29, 2008
- Last update posted
- Jun 2, 2010
2007 – 2008
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site 11 | Long Beach | California | — | — |
| Site 10 | Los Angeles | California | — | — |
| Site 13 | San Francisco | California | — | — |
| Site 5 | Miami | Florida | — | — |
| Site 4 | Orlando | Florida | — | — |
| Site 1 | Iowa City | Iowa | — | — |
| Site 7 | Louisville | Kentucky | — | — |
| Site 17 | Boston | Massachusetts | — | — |
| Site 8 | Ann Arbor | Michigan | — | — |
| Site 6 | Minneapolis | Minnesota | — | — |
| Site 18 | Long Branch | New Jersey | — | — |
| Site 16 | Albuquerque | New Mexico | — | — |
| Site 19 | Cincinnati | Ohio | — | — |
| Site 12 | Dayton | Ohio | — | — |
| Site 2 | Toledo | Ohio | — | — |
| Site 14 | Oklahoma City | Oklahoma | — | — |
| Site 3 | Hershey | Pennsylvania | — | — |
| Site 15 | Philadelphia | Pennsylvania | — | — |
| Site 9 | Nashville | Tennessee | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00510484, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 2, 2010 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00510484 live on ClinicalTrials.gov.